Oryzon Genomics SA: Funding, Investors & Team (Sep 2026)
Oryzon Genomics is a biopharmaceutical organization creating epigenetics-based therapeutics for patients with disease and CNS problems. Oryzon can distinguish and approve biomarkers and restorative focuses through its epigenetic stage and transform them into cutting edge and customized treatments. Oryzon Genomics has a developing portfolio, with two mixtures in Phase II clinical preliminaries: iadademstat (otherwise known as ORY-1001), a powerful and specific LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS enhanced LSD1 inhibitor for the treatment of neurological illnesses. The portfolio incorporates ORY-3001, a particular LSD1 inhibitor in preclinical improvement for the treatment of non-oncological illnesses.
Oryzon Genomics SA has raised $120M across 5 funding rounds on record, the most recent an undisclosed round of $15.5M announced in Jul 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Oryzon Genomics SA Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Oryzon Genomics SA Funding Rounds
Oryzon Genomics SA raised $20.5M in a Convertible Note announced in Jul 2022.
5 months later, an undisclosed round of $430k was announced in Dec 2022.
11 months later, an undisclosed round of $49.3M was announced in Nov 2023.
1.4 years later, an undisclosed round of $34.2M was announced in Apr 2025.
3 months later, an undisclosed round of $15.5M was announced in Jul 2025.
Oryzon Genomics SA Founders and Leadership Team
Contact details for the Oryzon Genomics SA team: 1 of 2 have an email address on file.
Start 14-day free trial →Oryzon Genomics SA Funding Compared to Other Biotechnology Startups
Oryzon Genomics SA's latest round of $15.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Oryzon Genomics SA in Biotechnology and Barcelona
Companies Similar to Oryzon Genomics SA
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun…
Oryzon Genomics SA Funding FAQs
What does Oryzon Genomics SA do?
Oryzon Genomics is a biopharmaceutical organization creating epigenetics-based therapeutics for patients with disease and CNS problems. Oryzon can distinguish and approve biomarkers and restorative focuses through its epigenetic stage and transform them into cutting edge and customized treatments. Oryzon Genomics has a developing portfolio, with two mixtures in Phase II clinical preliminaries: iadademstat (otherwise known as ORY-1001), a powerful and specific LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS enhanced LSD1 inhibitor for the treatment of neurological illnesses. The portfolio incorporates ORY-3001, a particular LSD1 inhibitor in preclinical improvement for the treatment of non-oncological illnesses.
How much funding has Oryzon Genomics SA raised?
Oryzon Genomics SA has raised $120M across 5 rounds on record. The most recent is an undisclosed round of $15.5M announced in Jul 2025.
When did Oryzon Genomics SA last raise funding?
Oryzon Genomics SA's most recent funding round on record is an undisclosed round of $15.5M, announced in Jul 2025.
Who founded Oryzon Genomics SA?
FundedIQ lists Carlos Buesa (Founder), Tamara Maes (Founder) at Oryzon Genomics SA.
Where is Oryzon Genomics SA headquartered?
Oryzon Genomics SA is based in Barcelona, Catalonia, Spain.
How many employees does Oryzon Genomics SA have?
Oryzon Genomics SA is in the 11-50 employee band.
How does Oryzon Genomics SA's funding compare to other Biotechnology startups?
Oryzon Genomics SA's latest round of $15.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Oryzon Genomics SA Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Oryzon Genomics SA is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.